choroidal neovascularization (CNV) is the common reason of visual acuity impairment in high myopia patients, which usually leads to irreversible central visual impairment.
This study was to evaluate the clinical efficacy and safety of conbercept intravitreal injection for CNV in high myopia.
Fifteen high myopia patients with macular CNV diagnosed by OCT and fluorescein fundus angiography (FFA) from July 2014 to July 2015 were retrospectively analyzed.All patients were performed with intravitreal injection of conbercept 0.5 mg (0.05 ml). The best corrected visual acuity (BCVA) and central macular thickness (CMT) were examined 1 day, l week, 4, 8 and 12 weeks after injection.The ocular and systemic complications relating to drug were also observed.
Fifteen eyes of 15 patients totally received 45 times of conbercept intravitreal injection.Among the total, 1 eye only received 1 time of treatment, 2 eyes received 2 times of treatment, 12 eyes received 3 times of treatment and 1 eye received 4 times of treatments.After 12 weeks of treatment, FFA showed that fluorescein leakage disappeared in 10 eyes; fluorescein leakage area decreased in 4 eyes; fluorescein leakage was continued in 1 eye.The BCVA before treatment and at 4, 8 and 12 weeks after treatment were 0.61±0.46, 0.60±0.43, 0.41±0.53 and 0.41±0.51, with significant difference among them ( F=7.862, P<0.001). The CMT before treatment and at 4, 8 and 12 weeks after treatment were (280.33±14.40), (269.00±10.10), (261.93±7.80) and (259.53±6.30)μm respectively, with significant difference among them (F=32.520, P<0.001). None of the patients conducted anterior chamber puncture because of elevated intraocular pressure, and no intraocular inflammation, vitreous hemorrhage, retinal detachment and cardiovascular disease or other serious complications occurred.
Intravitreal injection of conbercept can relieve macular edema and improve the vision.It is an effective method for the treatment of CNV associated with high myopia, but long-term follow-up observation still need to perform.